2023

• Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine

Muranishi K, Kinoshita M, Inoue K, Ohara J, Mihara T, Sudo K, Ishii KJ, Sawa T, Ishikura H.
Vaccines (Basel). 2023 Dec 20;12(1):5. doi: 10.3390/vaccines12010005.

• Virological characteristics of the SARS-CoV-2 JN.1 variant

Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA Jr, Chen L, Plianchaisuk A, Kobiyama K, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Zahradnik J, Ito J, Sato K.
Lancet Infect Dis. 2024 Feb;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7. Epub 2024 Jan 3.

• Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism

Palacpac NMQ, Ishii KJ, Arisue N, Tougan T, Horii T.
Parasitol Int. 2024 Apr:99:102845. doi: 10.1016/j.parint.2023.102845. Epub 2023 Dec 13.

• TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model

Castro Eiro MD, Hioki K, Li L, Wilmsen MEP, Kiernan CH, Brouwers-Haspels I, van Meurs M, Zhao M, de Wit H, Grashof DGB, van de Werken HJG, Mueller YM, Schliehe C, Temizoz B, Kobiyama K, Ishii KJ, Katsikis PD.
J Immunol. 2024 Feb 1;212(3):455-465. doi: 10.4049/jimmunol.2300038.

• Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci

Yokota C, Fujimoto K, Yamakawa N, Kono M, Miyaoka D, Shimohigoshi M, Uematsu M, Watanabe M, Kamei Y, Sugimoto A, Kawasaki N, Yabuno T, Okamura T, Kuroda E, Hamaguchi S, Sato S, Hotomi M, Akeda Y, Ishii KJ, Yasutomi Y, Sunami K, Uematsu S.
Inflamm Regen. 2023 Nov 15;43(1):55. doi: 10.1186/s41232-023-00305-2.

• Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

Ouédraogo A, Bougouma EC, Palacpac NMQ, Houard S, Nebie I, Sawadogo J, Berges GD, Soulama I, Diarra A, Hien D, Ouedraogo AZ, Konaté AT, Kouanda S, Myoui A, Ezoe S, Ishii KJ, Sato T, D’Alessio F, Leroy O, Tiono AB, Cousens S, Horii T, Sirima SB.
Front Immunol. 2023 Oct 16;14:1267372. doi: 10.3389/fimmu.2023.1267372. eCollection 2023.

• Akkermansia muciniphila induces slow extramedullary hematopoiesis via cooperative IL-1R/TLR signals

Wang Y, Morishima T, Sezaki M, Sato R, Nakato G, Fukuda S, Kobiyama K, Ishii KJ, Li Y, Takizawa H.
EMBO Rep. 2023 Oct 23:e57485. doi: 10.15252/embr.202357485.

• Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community’s view

Yao L, Chemaitelly H, Goldman E, Gudina EK, Khalil A, Ahmed R, James AB, Roca A, Fallah MP, Macnab A, Cho WC, Eikelboom J, Qamar FN, Kremsner P, Oliu-Barton M, Sisa I, Tadesse BT, Marks F, Wang L, Kim JH, Meng X, Wang Y, Fly AD, Wang CY, Day SW, Howard SC, Graff JC, Maida M, Ray K, Franco-Paredes C, Mashe T, Ngongo N, Kaseya J, Ndembi N, Hu Y, Bottazzi ME, Hotez PJ, Ishii KJ, Wang G, Sun D, Aleya L, Gu W.
EClinicalMedicine. 2023 Sep 26:64:102222. doi: 10.1016/j.eclinm.2023.102222.

• Challenges in developing personalized neoantigen cancer vaccines

Katsikis PD, Ishii KJ, Schliehe C.
Nat Rev Immunol. 2023 Oct 2. doi: 10.1038/s41577-023-00937-y.

• Identification of a Self-Assembling Small-Molecule Cancer Vaccine Adjuvant with an Improved Toxicity Profile

Zhuo SH, Noda N, Hioki K, Jin S, Hayashi T, Hiraga K, Momose H, Li WH, Zhao L, Mizukami T, Ishii KJ, Li YM, Uesugi M.
J Med Chem. 2023 Sep 7. doi: 10.1021/acs.jmedchem.3c01252.

• Secretion of mitochondrial DNA via exosomes promotes inflammation in Behçet’s syndrome

Konaka H, Kato Y, Hirano T, Tsujimoto K, Park J, Koba T, Aoki W, Matsuzaki Y, Taki M, Koyama S, Itotagawa E, Jo T, Hirayama T, Kawai T, Ishii KJ, Ueda M, Yamaguchi S, Akira S, Morita T, Maeda Y, Nishide M, Nishida S, Shima Y, Narazaki M, Takamatsu H, Kumanogoh A.
EMBO J. 2023 Sep 4:e112573. doi: 10.15252/embj.2022112573.

• Intratumoural Delivery of mRNA Loaded on a Cationic Hyper-Branched Cyclodextrin-Based Polymer Induced an Anti-Tumour Immunological Response in Melanoma

Khazaei Monfared Y, Mahmoudian M, Zakeri-Milani P, Cecone C, Hayashi T, Ishii KJ, Conde J, Matencio A, Trotta F.
Cancers (Basel). 2023 Jul 24;15(14):3748. doi: 10.3390/cancers15143748.

• Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody

Saito Y, Takahashi T, Hiramatsu K, Serada S, Fujimoto M, Ohkawara T, Sugase T, Nishigaki T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Ishii KJ, Eguchi H, Doki Y, Naka T.
Anticancer Res. 2023 Jun;43(6):2425-2432. doi: 10.21873/anticanres.16410.

• Dendritic cell proliferation by primary cilium in atopic dermatitis

Toriyama M, Rizaldy D, Nakamura M, Atsumi Y, Toriyama M, Fujita F, Okada F, Morita A, Itoh H, Ishii KJ.
Front Mol Biosci. 2023 Apr 26;10:1149828. doi: 10.3389/fmolb.2023.1149828. eCollection 2023.

• Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice

Ito D, Ito H, Ando T, Sakai Y, Ideta T, Ishii KJ, Ishikawa T, Shimizu M.
Hepatol Commun. 2023 Mar 24;7(4):e0104. doi: 10.1097/HC9.0000000000000104.

• A-910823, a Squalene-Based Emulsion Adjuvant, Induces T Follicular Helper Cells and Humoral Immune Responses via α-Tocopherol Component

Yoshioka Y, Kobiyama K, Hayashi T, Onishi M, Yanagida Y, Nakagawa T, Hashimoto M, Nishinaka A, Hirose J, Asaoka Y, Tajiri M, Hayata A, Ishida S, Omoto S, Nagira M, Ishii KJ.
Front. Immunol. 2023. doi: 10.3389/fimmu.2023.1116238.

• Roles of TRPM4 in immune responses in keratinocytes and identification of a novel TRPM4-activating agent

Otsuka Saito K, Fujita F, Toriyama M, Utami RA, Guo Z, Murakami M, Kato H, Suzuki Y, Okada F, Tominaga M, Ishii KJ.
Biochem Biophys Res Commun. 2023 Feb 24;654:1-9. doi: 10.1016/j.bbrc.2023.02.062.

• TLR4 agonist activity of Alcaligenes lipid a utilizes MyD88 and TRIF signaling pathways for efficient antigen presentation and T cell differentiation by dendritic cells

Sun X, Hosomi K, Shimoyama A, Yoshii K, Lan H, Wang Y, Yamaura H, Nagatake T, Ishii KJ, Akira S, Kiyono H, Fukase K, Kunisawa J.
Int Immunopharmacol. 2023 Feb 18;117:109852. doi: 10.1016/j.intimp.2023.109852.

• Anti-Inflammatory Role of TRPV4 in Human Macrophages

Atsumi Y, Toriyama M, Kato H, Nakamura M, Morita A, Takaishi M, Saito K, Tanaka M, Okada F, Tominaga M, Ishii KJ, Fujita F.
Immunohorizons. 2023 Jan 1;7(1):81-96. doi: 10.4049/immunohorizons.2200100.

2022

• Alveolar macrophages instruct CD8+ T cell expansion by antigen cross-presentation in lung

Kawasaki T, Ikegawa M, Yunoki K, Otani H, Ori D, Ishii KJ, Kuroda E, Takamura S, Kitabatake M, Ito T, Isotani A, Kawai T.
Cell Rep. 2022 Dec 13;41(11):111828. doi: 10.1016/j.celrep.2022.111828.

• Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein

Otsubo R, Minamitani T, Kobiyama K, Fujita J, Ito T, Ueno S, Anzai I, Tanino H, Aoyama H, Matsuura Y, Namba K, Imadome KI, Ishii KJ, Tsumoto K, Kamitani W, Yasui T.
Sci. Rep. 2022 Nov 22;12(1):20120. doi: 10.1038/s41598-022-24730-4.

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5

Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium, Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K.
Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14.

• Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan

Nomura Y, Noda K, Oohashi Y, Okuda S, Matsumoto J, Nakano T, Tsuchida N, Ishii KJ, Hayashi K, Iiyama T, Onodera H, Ishii K, Shikano M, Okabe N.
Vaccine. 2022 Sep 24:S0264-410X(22)01144-6. doi: 10.1016/j.vaccine.2022.09.036. Online ahead of print.

• Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, Aly HH, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Goh Y, Ishii KJ, Yotsuyanagi H, Muramatsu M, Ishii K, Takahashi Y, Suzuki R, Akari H, Kato T.
Nat Commun. 2022 Sep 5;13(1):5207. doi: 10.1038/s41467-022-32910-z.

• CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study

Otsuka T, Nishida S, Shibahara T, Temizoz B, Hamaguchi M, Shiroyama T, Kimura K, Miyake K, Hirata H, Mizuno Y, Yagita M, Manabe Y, Kuroda E, Takeda Y, Kida H, Ishii KJ, Kumanogoh A.
BMC Cancer. 2022 Jul 7;22(1):744. doi: 10.1186/s12885-022-09818-4.

• Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases

Ishii KJ.
Yakugaku Zasshi. 2022;142(7):709-713. doi: 10.1248/yakushi.21-00210-5.

• Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation

Yamada S, Kitai Y, Tadokoro T, Takahashi R, Shoji H, Maemoto T, Ishiura M, Muromoto R, Kashiwakura JI, Ishii KJ, Maenaka K, Kawai T, Matsuda T.
J Immunol. 2022 Jul 1;209(1):171-179. doi: 10.4049/jimmunol.2100963. Epub 2022 Jun 20.

• Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial

Watanabe A, Nishida S, Burcu T, Shibahara T, Kusakabe T, Kuroda E, Ishii KJ, Kumanogoh A.
Vaccine. 2022 Jul 29;40(31):4150-4159. doi: 10.1016/j.vaccine.2022.05.060. Epub 2022 Jun 4.

• Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants

Hioki K, Hayashi T, Natsume-Kitatani Y, Kobiyama K, Temizoz B, Negishi H, Kawakami H, Fuchino H, Kuroda E, Coban C, Kawahara N, Ishii KJ.
Front Immunol. 2022 May 19;13:847616. doi: 10.3389/fimmu.2022.847616. eCollection 2022.

• Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K.
Cell 2022 May 2:S0092-8674(22)00533-5. doi: 10.1016/j.cell.2022.04.035. Online ahead of print.

• Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation

Temizoz B, Hioki K, Kobari S, Jounai N, Kusakabe T, Lee MSJ, Coban C, Kuroda E, Ishii KJ.
Int Immunol. 2022 Apr 14;dxac012. doi: 10.1093/intimm/dxac012. Online ahead of print.

• Making innate sense of mRNA vaccine adjuvanticity

Kobiyama K, Ishii KJ.
Nat Immunol. 2022 Apr;23(4):474-476. doi: 10.1038/s41590-022-01168-4.

• Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan

Nomura Y, Noda K, Oohashi Y, Okuda S, Maki K, Ogawa T, Nakano T, Tsuchida N, Ishii KJ, Hayashi K, Iiyama T, Onodera H, Ishii K, Shikano M, Okabe N.
Vaccine. 2022 Apr 26;40(19):2810-2818. doi: 10.1016/j.vaccine.2022.03.043. Epub 2022 Mar 24.

• In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy

Okada H, Takahashi K, Yaku H, Kobiyama K, Iwaisako K, Zhao X, Shiokawa M, Uza N, Kodama Y, Ishii KJ, Seno H.
Sci Rep. 2022 Feb 8;12(1):2132. doi: 10.1038/s41598-022-05702-0.

• B cell-intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice

Lee MSJ, Inoue T, Ise W, Matsuo-Dapaah J, Wing JB, Temizoz B, Kobiyama K, Hayashi T, Patil A, Sakaguchi S, Simon AK, Bezbradica JS, Nagatoishi S, Tsumoto K, Inoue JI, Akira S, Kurosaki T, Ishii KJ, Coban C.
J Exp Med. 2022 Feb 7;219(2):e20211336. doi: 10.1084/jem.20211336. Epub 2021 Dec 15. Online ahead of print.

2021

• S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes

Nakagawa T, Tanino T, Onishi M, Tofukuji S, Kanazawa T, Ishioka Y, Itoh T, Kugimiya A, Katayama K, Yamamoto T, Nagira M, Ishii KJ.
Front Immunol. 2021 Dec 23;12:803090. doi: 10.3389/fimmu.2021.803090. eCollection 2021.

• Using a new three-dimensional CUBIC tissue-clearing method to examine the brain during experimental cerebral malaria

Julia Matsuo-Dapaah, Michelle Sue Jann Lee, Ishii KJ, Kazuki Tainaka, and Cevayir Coban.
Int Immunol. 2021 Aug 29;dxab060. doi: 10.1093/intimm/dxab060.

• Type I and II interferons toward ideal vaccine and immunotherapy

Temizoz B, and Ishii KJ.
Expert Rev Vaccines. 2021 Jun 9:1-18. doi: 10.1080/14760584.2021.1927724.

• Increase in primary cilia in the epidermis of patients with atopic dermatitis and psoriasis.

Rizaldy D, Toriyama M, Kato H, Fukui R, Fujita F, Nakamura M, Okada F, Morita A, and Ishii KJ.
Exp Dermatol. 2021 Jun;30(6):792-803. doi: 10.1111/exd.14285.

• Primary Cilia in the Skin: Functions in Immunity and Therapeutic Potential

Toriyama M, and Ishii KJ.
Front Cell Dev Biol. 2021 Feb 11;9:621318. doi: 10.3389/fcell.2021.621318. eCollection 2021.

• Discovery of Self-Assembling Small Molecules as Vaccine Adjuvants.

Jin S, Vu HT, Hioki K, Noda N, Yoshida H, Shimane T, Ishizuka S, Takashima I, Mizuhata Y, Pe KB, Ogawa T, Nishimura N, Packwood D, Tokitoh N, Kurata H, Yamasaki S, Ishii KJ, and Uesugi M.
Angew Chem Int Ed Engl. 2021 Jan 11;60(2):961-969. doi: 10.1002/anie.202011604

2020年

• First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).

Ezoe S, Palacpac NMQ, Tetsutani K, Yamamoto K, Okada K, Taira M, Nishida S, Hirata H, Ogata A, Yamada T, Yagi M, Edula JR, Oishi Y, Tougan T, Ishii KJ, Myoui A, and Horii T.
Vaccine. 2020 Oct 1:S0264-410X(20)31227-5. doi: 10.1016/j.vaccine.2020.09.056.

• The Ca2+-dependent pathway contributes to changes in the subcellular localization and extracellular release of interleukin-33.

Momota M, Nagayama M, Okude H, Ishii KJ, Ori D, Kawasaki T, and Kawai T.
Biochem Biophys Res Commun. 2020 Oct 1;530(4):699-705. doi: 10.1016/j.bbrc.2020.07.127. Epub 2020 Aug 5.

• Strategic Outlook toward 2030: Japan’s research for allergy and immunology – Secondary publication.

Adachi T, Kainuma K, Asano K, Amagai M, Arai H, Ishii KJ , Ito K, Uchio E, Ebisawa M, Okano M, Kabashima K, Kondo K, Konno S, Saeki H, Sonobe M, Nagao M, Hizawa N, Fukushima A, Fujieda S, Matsumoto K, Morita H, Yamamoto K, Yoshimoto A, and Tamari M.
Allergol Int. 2020 Oct;69(4):561-570. doi: 10.1016/j.alit.2020.04.006. Epub 2020 Jun 27.

• Lung fibroblasts produce IL-33 in response to stimulation with retinoblastoma-binding protein 9 via production of prostaglandin E2.

Adachi T, Yasuda K, Muto T, Serada S, Yoshimoto T, Ishii KJ, Kuroda E, Araki K, Ohmuraya M, Naka T, and Nakanishi K.
Int Immunol. 2020 Sep 30;32(10):637-652. doi: 10.1093/intimm/dxaa031.

• IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination.

Kobari S, Kusakabe T, Momota M, Shibahara T, Hayashi T, Ozasa K, Morita H, Matsumoto K, Saito H, Ito S, Kuroda E, and Ishii KJ.
Front Immunol. 2020 Mar 6;11:360. doi: 10.3389/fimmu.2020.00360. eCollection 2020.

• Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant.

Ito S, Hirobe S, Kawakita T, Saito M, Quan YS, Kamiyama F, Ishii KJ, Nagao M, Fujisawa T, Tachibana M, and Okada N.
Pharmaceutics. 2020 Mar 15;12(3):267. doi: 10.3390/pharmaceutics12030267.

• Heparin induces neutrophil elastase-dependent vital and lytic NET formation.

Lelliott PM, Momota M, Shibahara T, Lee MSJ, Smith NI, Ishii KJ, and Coban C.
Int Immunol. 2020 May 8;32(5):359-368. doi: 10.1093/intimm/dxz084.

• ZBP1 governs the inflammasome-independent IL-1α and neutrophil inflammation that play a dual role in anti-influenza virus immunity.

Momota M, Lelliott P, Kubo A, Kusakabe T, Kobiyama K, Kuroda E, Imai Y, Akira S, Coban C, and Ishii KJ.
Int Immunol. 2020 Mar 7;32(3):203-212. doi: 10.1093/intimm/dxz070.

2019

• Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor.

Ozasa K, Temizoz B, Kusakabe T, Kobari S, Momota M, Coban C, Ito S, Kobiyama K, Kuroda E, and Ishii KJ.
Front Immunol. 2019 Sep 26;10:2212. doi: 10.3389/fimmu.2019.02212. eCollection 2019.

• Interleukin-1/-33 Signaling Pathways as Therapeutic Targets for Endometriosis.

Kato T, Yasuda K, Matsushita K, Ishii KJ, Hirota S, Yoshimoto T, and Shibahara H.
Front Immunol. 2019 Aug 22;10:2021. doi: 10.3389/fimmu.2019.02021. eCollection 2019.

• Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies.

Adachi Y, Tonouchi K, Nithichanon A, Kuraoka M, Watanabe A, Shinnakasu R, Asanuma H, Ainai A, Ohmi Y, Yamamoto T,and Ishii KJ, Hasegawa H, Takeyama H, Lertmemongkolchai G, Kurosaki T, Ato M, Kelsoe G, Takahashi Y.
Nat Commun. 2019 Aug 28;10(1):3883. doi: 10.1038/s41467-019-11821-6.

• Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases.

Fujimoto K, Kawaguchi Y, Shimohigoshi M, Gotoh Y, Nakano Y, Usui Y, Hayashi T, Kimura Y, Uematsu M, Yamamoto T, Akeda Y, Rhee JH, Yuki Y, Ishii KJ, Crowe SE, Ernst PB, Kiyono H, and Uematsu S.
Gastroenterology. 2019 Dec;157(6):1530-1543.e4. doi: 10.1053/j.gastro.2019.08.021. Epub 2019 Aug 21.

• Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection.

Leach S, Shinnakasu R, Adachi Y, Momota M, Makino-Okamura C, Yamamoto T, Ishii KJ, Fukuyama H, Takahashi Y, and Kurosaki T. Int Immunol. 2019 Nov 8;31(12):771-779. doi: 10.1093/intimm/dxz049.

• BLT1 mediates commensal bacteria-dependent innate immune signals to enhance antigen-specific intestinal IgA responses.

Nagatake T, Hirata SI, Koga T, Kuroda E, Kobari S, Suzuki H, Hosomi K, Matsumoto N, Yanrismet Y, Shimojou M, Morimoto S, Sasaki F, Ishii KJ, Yokomizo T, and Kunisawa J.
Mucosal Immunol. 2019 Sep;12(5):1082-1091. doi: 10.1038/s41385-019-0175-z. Epub 2019 May 29.

• B cell-intrinsic MyD88 signaling controls IFNγ-mediated early IgG2c class switching in mice in response to a particulate adjuvant.

Lee MSJ, Natsume-Kitatani Y, Temizoz B, Fujita Y, Konishi A, Matsuda K, Igari Y, Tsukui T, Kobiyama K, Kuroda E, Onishi M, Marichal T, Ise W, Inoue T, Kurosaki T, Mizuguchi K, Akira S, Ishii KJ, and Coban C.
Eur J Immunol. 2019 May 14. doi: 10.1002/eji.201848084. [Epub ahead of print]

• Rapid Quantification of NETs In Vitro and in Whole Blood Samples by Imaging Flow Cytometry.

Lelliott PM, Momota M, Lee MSJ, Kuroda E, Iijima N, Ishii KJ, and Coban C.
Cytometry A. 2019 May;95(5):565-578. doi: 10.1002/cyto.a.23767. Epub 2019 Apr 15.

• STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques.

Yamamoto T, Kanuma T, Takahama S, Okamura T, Moriishi E, Ishii KJ, Terahara K, and Yasutomi Y.
Sci Rep. 2019 Apr 11;9(1):5917. doi: 10.1038/s41598-019-42253-3.

• Cholera toxin B induces interleukine-1β production from resident peritoneal macrophages through pyrin as well as NLRP3 inflammasome.

Orimo T, Sasaki I, Hemmi H, Ozasa T, Fukuda-Ohta Y, Ohta T, Morinaka M, Kitauchi M, Yamaguchi T, Sato Y, Tanaka T, Hoshino K, Katayama KI, Fukuda S, Miyake K, Yamamoto M, Satoh T, Furukawa K, Kuroda E, Ishii KJ, Takeda K, and Kaisho T.
Int Immunol. 2019 Jan 25. doi: 10.1093/intimm/dxz004. [Epub ahead of print]

• Reciprocal regulation of STING and TCR signaling by mTORC1 for T-cell activation and function.

Imanishi T, Unno M, Kobayashi W, Yoneda N, Matsuda S, Ikeda K, Hoshii T, Hirao A, Miyake K, Barber GN, Arita M,
Ishii KJ, Akira S, and Saito T.
Life Sci Alliance. 2019 Jan 25;2(1). pii: e201800282. doi: 10.26508/lsa.201800282. Print 2019 Feb.

• A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Yamamoto T, Masuta Y, Momota M, Kanekiyo M, Kanuma T, Takahama S, Moriishi E, Yasutomi Y, Saito T, Graham BS, Takahashi Y, and Ishii KJ.
Int Immunol. 2019 Feb 15;31(2):81-90. doi: 10.1093/intimm/dxy069.

2018

• DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.

Hayashi T, Momota M, Kuroda E, Kusakabe T, Kobari S, Makisaka K, Ohno Y, Suzuki Y, Nakagawa F, Lee MSJ, Coban C, Onodera R, Higashi T, Motoyama K, Ishii KJ, and Arima H.
Front Immunol. 2018 Nov 20;9:2619. doi: 10.3389/fimmu.2018.02619. eCollection 2018.

• Pulmonary phagocyte-derived NPY controls the pathology of severe influenza virus infection.

Fujiwara S, Hoshizaki M, Ichida Y, Lex D, Kuroda E, Ishii KJ, Magi S, Okada M, Takao H, Gandou M, Imai H, Hara R, Herzog H, Yoshimura A, Okamura H, Penninger JM, Slutsky AS, Uhlig S, Kuba K, and Imai Y
Nat Microbiol. 2018, Feb;4(2):258-268. doi: 10.1038/s41564-018-0289-1.

• The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.

Naito Y, Hamaoka S, Kinoshita M, Kainuma A, Shimizu M, Katoh H, Moriyama K, Ishii KJ, and Sawa T
Microbiol Immunol. 2018 Dec;62(12):774-785. doi: 10.1111/1348-0421.12658.

• Corrigendum to “Designing an immunocyte-targeting delivery system by use of beta-glucan

Miyamoto N, Mochizuki S, Kobiyama K, Ishii KJ, and Sakurai K
Vaccine. 2018 Oct 29;36(45):6892. doi: 10.1016/j.vaccine.2018.09.047

• Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation

Matsumoto R, Dainichi T, Tsuchiya S, Nomura T, Kitoh A, Hayden MS,Ishii KJ, Tanaka M, Honda T, Egawa G, Otsuka A, Nakajima S, Sakurai K, Nakano Y, Kobayashi T, Sugimoto Y, and Kabashima K.
JCI Insight. 2018 Aug 9;3(15). pii: 121175. doi: 10.1172/jci.insight.121175. eCollection 2018 Aug 9

• Development of screening method for intranasal influenza vaccine and adjuvant safety in preclinical study

Hiradate Y, Sasaki E, Momose H, Asanuma H, Furuhata K, Takai M, Aoshi T,Yamada H, Ishii KJ, Tanemura K, Mizukami T, and Hamaguchi I.
Biologicals. 2018 Sep;55:43-52. doi: 10.1016/j.biologicals.2018.07.001. Epub 2018 Jul 14.

• Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice.

Nagatake T, Suzuki H, Hirata SI, Matsumoto N, Wada Y, Morimoto S, Nasu A, Shimojou M, Kawano M, Ogami K, Tsujimura Y,Kuroda E, Iijima N, Hosomi K, Ishii KJ, Nosaka T, Yasutomi Y, and Kunisawa J.
Int Immunol. 2018 Sep 25;30(10):471-481. doi: 10.1093/intimm/dxy046.

• Combination and inducible adjuvants targeting nucleic acid sensors.

Temizoz B, Kuroda E, and Ishii KJ.
Curr Opin Pharmacol. 2018 Aug;41:104-113. doi: 10.1016/j.coph.2018.05.003. Epub 2018 Jun 2.

• Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.

Takahashi H, Misato K, Aoshi T, Yamamoto Y, Kubota Y, Wu X, Kuroda E, Ishii KJ , Yamamoto H, and Yoshioka Y.
Front Immunol. 2018 Apr 18;9:783. doi: 10.3389/fimmu.2018.00783. eCollection 2018.

• Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner.

Katayama Y, Tachibana M, Kurisu N, Oya Y, Terasawa Y, Goda H, Kobiyama K, Ishii KJ, Akira S, Mizuguchi H, and Sakurai F.
J Immunol. 2018 Apr 15;200(8):2987-2999. doi: 10.4049/jimmunol.1700435. Epub 2018 Mar 19.

• Lymphoid tissue-resident Alcaligenes LPS induces IgA production without excessive inflammatory responses via weak TLR4 agonist activity.

Shibata N, Kunisawa J, Hosomi K, Fujimoto Y, Mizote K, Kitayama N, Shimoyama A, Mimuro H, Sato S, Kishishita N, Ishii KJ, Fukase K, and Kiyono H.
Mucosal Immunol. 2018 May;11(3):693-702. doi: 10.1038/mi.2017.103. Epub 2018 Feb 7.

• An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates.

Masuta Y, Yamamoto T, Natsume-Kitatani Y, Kanuma T, Moriishi E, Kobiyama K, Mizuguchi K, Yasutomi Y, and Ishii KJ.
J Immunol. 2018 Mar 15;200(6):2067-2075. doi: 10.4049/jimmunol.1701183. Epub 2018 Feb 5.

• Eosinophil depletion suppresses radiation-induced small intestinal fibrosis.

HTakemura N, Kurashima Y, Mori Y, Okada K, Ogino T, Osawa H, Matsuno H,Aayam L, Kaneto S, Park EJ, Sato S, Matsunaga K, Tamura Y, Ouchi Y, KumagaiY, Kobayashi D, Suzuki Y, Yoshioka Y, Nishimura J, Mori M, Ishii KJ, Rothenberg ME, Kiyono H, Akira S, and Uematsu S. Sci Transl Med. 2018 Feb 21;10(429). pii: eaan0333. doi: 10.1126/scitranslmed.aan0333.

• Modeling for influenza vaccines and adjuvants profile for safety prediction system using gene expression profiling and statistical tools.

Sasaki E, Momose H, Hiradate Y, Furuhata K, Takai M, Asanuma H, Ishii KJ, Mizukami T, and Hamaguchi I.
PLoS One. 2018 Feb 6;13(2):e0191896. doi: 10.1371/journal.pone.0191896. eCollection 2018.

• Tissue-specific immunopathology during malaria infection.

Coban C, Lee MSJ, and Ishii KJ.
Nat Rev Immunol. 2018 Apr;18(4):266-278. doi: 10.1038/nri.2017.138. Epub 2018 Jan 15.

• Essential Role of CARD14 in Murine Experimental Psoriasis.

Tanaka M, Kobiyama K, Honda T, Uchio-Yamada K, Natsume-Kitatani Y, Mizuguchi K, Kabashima K, and Ishii KJ.
J Immunol. 2018 Jan 1;200(1):71-81. doi: 10.4049/jimmunol.1700995. Epub 2017 Nov 17.

2017

• Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines.

Sasaki E, Momose H, Hiradate Y, Furuhata K, Takai M, Kamachi K, Asanuma H, Ishii KJ, Mizukami T, and Hamaguchi I.
Biologicals. 2017 Nov;50:100-108. doi: 10.1016/j.biologicals.2017.08.003. Epub 2017 Aug 31.

• Plasmodium products persist in the bone marrow and promote chronic bone loss.

Lee MSJ, Maruyama K, Fujita Y, Konishi A, Lelliott PM, Itagaki S, Horii T, Lin JW, Khan SM, Kuroda E, Akira S, Ishii KJ, and Coban C.
Sci Immunol. 2017 Jun 2;2(12). pii: eaam8093. doi: 10.1126/sciimmunol.aam8093.

• Isoflurane is a suitable alternative to ether for anesthetizing rats prior to euthanasia for gene expression analysis.

Nakatsu N, Igarashi Y, Aoshi T, Hamaguchi I, Saito M, Mizukami T, Momose H, Ishii KJ, and Yamada H.
J Toxicol Sci. 2017;42(4):491-497. doi: 10.2131/jts.42.491.

• Inflammasome and Fas-Mediated IL-1β Contributes to Th17/Th1 Cell Induction in Pathogenic Bacterial Infection In Vivo.

Uchiyama R, Yonehara S, Taniguchi S, Ishido S, Ishii KJ, and Tsutsui H.
J Immunol. 2017 Aug 1;199(3):1122-1130. doi: 10.4049/jimmunol.1601373. Epub 2017 Jul 3.

• CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+ T Cell Responses.

Kanuma T, Yamamoto T, Kobiyama K, Moriishi E, Masuta Y, Kusakabe T, Ozasa K, Kuroda E, Jounai N, and Ishii KJ.
J Immunol. 2017 Jun 15;198(12):4707-4715. doi: 10.4049/jimmunol.1600731. Epub 2017 May 15.

• Human Scavenger Receptor A1-Mediated Inflammatory Response to Silica Particle Exposure Is Size Specific.

Nishijima N, Hirai T, Misato K, Aoyama M, Kuroda E, Ishii KJ, Higashisaka K, Yoshioka Y, and Tsutsumi Y.
Front Immunol. 2017 Apr 3;8:379. doi: 10.3389/fimmu.2017.00379. eCollection 2017.

• Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.

Hamaoka S, Naito Y, Katoh H, Shimizu M, Kinoshita M, Akiyama K, Kainuma A, Moriyama K, Ishii KJ, and Sawa T.
Microbiol Immunol. 2017 Feb;61(2):64-74. doi: 10.1111/1348-0421.12467.

• Allergic Responses Induced by the Immunomodulatory Effects of Nanomaterials upon Skin Exposure.

Yoshioka Y, Kuroda E, Hirai T, Tsutsumi Y, and Ishii KJ.
Front Immunol. 2017 Feb 16;8:169. doi: 10.3389/fimmu.2017.00169. eCollection 2017.

• Mapping circulating serum miRNAs to their immune-related target mRNAs.

Nosirov B, Billaud J, Vandenbon A, Diez D, Wijaya E, Ishii KJ, Teraguchi S, and Standley DM.
Adv Appl Bioinform Chem. 2017 Feb 2;10:1-9. doi: 10.2147/AABC.S121598. eCollection 2017.

• Particulates Induce Type-2 Immune Responses. 【PDF】

Kuroda E and Ishii KJ.
Nihon Eiseigaku Zasshi. 2017;72(1):27-31. doi: 10.1265/jjh.72.27. Japanese.

• Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection. 【PDF】

Jounai N, Yoshioka M, Tozuka M, Inoue K, Oka T, Miyaji K, Ishida K, KawaiN, Ikematsu H, Kawakami C, Shimizu H, Mori M, Ishii KJ, and Takeshita F.
EBioMedicine. 2017 Feb;16:124-135. doi: 10.1016/j.ebiom.2017.01.014. Epub 2017 Jan 16.

• DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.

Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, Akira S, Matsuda T, and Kawai T.
J Immunol. 2017 Feb 15;198(4):1649-1659. doi: 10.4049/jimmunol.1601694. Epub 2017 Jan 9.

• A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests.

Sasaki E, Kuramitsu M, Momose H, Kobiyama K, Aoshi T, Yamada H, Ishii KJ, Mizukami T, and Hamaguchi I.
Vaccine. 2017 Feb 1;35(5):821-830. doi: 10.1016/j.vaccine.2016.12.036. Epub 2017 Jan 4.

2016

• Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1α Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation.

Kuroda E, Ozasa K, Temizoz B, Ohata K, Koo CX, Kanuma T, Kusakabe T, Kobari S, Horie M, Morimoto Y, Nakajima S, Kabashima K, Ziegler SF, Iwakura Y, Ise W, Kurosaki T, Nagatake T, Kunisawa J, Takemura N, Uematsu S, Hayashi Hayashi M, Aoshi T, Haseda Y, Kobiyama K, Wijaya E, Nakatsu N, Igarashi M, Aoshi T, Kobiyama K, Coban C, and Ishii KJ.
Immunity. 2016 Dec 20;45(6):1299-1310. doi: 10.1016/j.immuni.2016.11.010.

• Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.

Hayashi M, Aoshi T, Haseda Y, Kobiyama K, Wijaya E, Nakatsu N, Igarashi Y, Standley DM, Yamada H, Honda-Okubo Y, Hara H, Saito T, Takai T, Coban C, Petrovsky N, and Ishii KJ.
EBioMedicine. 2017 Feb;15:127-136. doi: 10.1016/j.ebiom.2016.11.015. Epub 2016 Dec 1.

• Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.

Ito H, Ando T, Nakamura M, Ishida H, Kanbe A, Kobiyama K, Yamamoto T, Ishii KJ, Hara A, Seishima M, and Ishikawa T.
J Viral Hepat. 2017 Feb;24(2):155-162. doi: 10.1111/jvh.12629. Epub 2016 Nov 3.

• Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.

Yokokawa H, Higashino A, Suzuki S, Moriyama M, Nakamura N, Suzuki T, Suzuki R, Ishii K, Kobiyama K, Ishii KJ, Wakita T, Akari H, and Kato T.
Gut. Gut. 2018 Feb;67(2):372-379. doi: 10.1136/gutjnl-2016-312208. Epub 2016 Oct 26.

• Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells. 【PDF】

Kitahata Y, Kanuma T, Hayashi M, Kobayashi N, Ozasa K, Kusakabe T, Temizoz B, Kuroda E, Yamaue H, Coban C, Yamamoto T, Kobiyama K, Aoshi T, and Ishii KJ.
Oncotarget. 2016 Aug 2;7(31):48860-48869. doi: 10.18632/oncotarget.10379.

• RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine. 【PDF】

Hayashi M, Aoshi T, Ozasa K, Kusakabe T, Momota M, Haseda Y, Kobari S, Kuroda E, Kobiyama K, Coban C, and Ishii KJ
Sci Rep. 2016 Jul 4;6:29165. doi: 10.1038/srep29165.

• Ligand-induced Ordering of the C-terminal Tail Primes STING for Phosphorylation by TBK1. 【PDF】

Tsuchiya Y,Jounai N, Takeshita F, Ishii KJ, and Mizuguchi K.
EBioMedicine. 2016 Jul;9:87-96. doi: 10.1016/j.ebiom.2016.05.039. Epub 2016 Jun 1.

• Metal nanoparticles in the presence of lipopolysaccharides trigger the onset of metal allergy in mice.

Hirai T, Yoshioka Y, Izumi N, Ichihashi KI, Handa T, Nishijima N, Uemura E, Sagami KI, Takahashi H, Yamaguchi M, Nagano K, Mukai Y, Kamada H, Tsunoda SI, Ishii KJ, Higashisaka K, and Tsutsumi Y.
Nat Nanotechnol. 2016 Sep;11(9):808-16. doi: 10.1038/nnano.2016.88. Epub 2016 May 30.

• Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.

Shiraishi K, Kawano K, Maitani Y, Aoshi T, Ishii KJ, Sanada Y, Mochizuki S, Sakurai K, and Yokoyama M.
J Control Release. 2016 Jul 28;234:59-67. doi: 10.1016/j.jconrel.2016.05.010. Epub 2016 May 6.

• Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.

Kusakabe T, Ozasa K, Kobari S, Momota M, Kishishita N, Kobiyama K, Kuroda E, and Ishii KJ.
Vaccine. Vaccine. 2016 Jun 8;34(27):3191-3198. doi: 10.1016/j.vaccine.2016.04.001. Epub 2016 May 6.

• High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis.

Hirai T, Yoshioka Y, Takahashi H, Handa T, Izumi N, Mori T, Uemura E, Nishijima N, Sagami KI, Yamaguchi M, Eto SI, Nagano K, Kamada H, Tsunoda SI, Ishii KJ, Higashisaka K, and Tsutsumi Y.
Clin Exp Allergy. 2016 Jul;46(7):992-1003. doi: 10.1111/cea.12722. Epub 2016 May 3.

• Vaccine adjuvants as potential cancer immunotherapeutics. 【PDF】

Temizoz B, Kuroda E, and Ishii KJ.
Int Immunol. 2016 Jul;28(7):329-38. doi: 10.1093/intimm/dxw015. Epub 2016 Mar 22.

• Crucial roles of XCR1-expressing dendritic cells and the XCR1-XCL1 chemokine axis in intestinal immune homeostasis.

Ohta T, Sugiyama M, Hemmi H, Yamazaki C, Okura S, Sasaki I, Fukuda Y, Orimo T, Ishii KJ, Hoshino K, Ginhoux F, and Kaisho T.
Sci Rep. 2016 Mar 23;6:23505. doi: 10.1038/srep23505.

• Current status of synthetic hemozoin adjuvant: A preliminary safety evaluation.

Lee MS, Igari Y, Tsukui T, Ishii KJ, and Coban C.
Vaccine. 2016 Apr 19;34(18):2055-61. doi: 10.1016/j.vaccine.2016.02.064. Epub 2016 Mar 11.

• Monocyte infiltration into obese and fibrilized tissues is regulated by PILRα.

Kohyama M, Matsuoka S, Shida K, Sugihara F, Aoshi T, Kishida K, Ishii KJ, and Arase H.
Eur J Immunol. 2016 May;46(5):1214-23. doi: 10.1002/eji.201545897. Epub 2016 Feb 22.

• Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.

Kobiyama K, Temizoz B, Kanuma T, Ozasa K, Momota M, Yamamoto T, Aoshi T, Kuroda E, and Ishii KJ
Eur J Immunol. 2016 May;46(5):1142-51. doi: 10.1002/eji.201546059. Epub 2016 Feb 9.

• Screening of posttranscriptional regulatory molecules of IκB-ζ.

MaruYama T, Sayama A, Ishii KJ, and Muta T.
Biochem Biophys Res Commun. 2016 Jan 15;469(3):711-5. doi: 10.1016/j.bbrc.2015.12.068. Epub 2015 Dec 19.

2015

• 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.

Arato T, Daimon T, Heike Y, Ishii K, Itho K, Kageyama S, Kawakami Y, NakayamaE, Ozawa K, Sato N, Shiku H, Takeuchi M, Tani K, Tamada K, Ueda R, Yamaguchi Y, Yamanaka T, Yamaue H, Yasukawa M, Iguchi T, Kitano S, Miyahara Y, Nagata Y, Noguchi M, Terashima T, Asano T, Asonuma M, Ikeda H, Kakimi K, Takesako K, Tanaka M, Amakasu K, Yamada A, Harada N, Aoshi T, Kuroda E, Kobiyama K, Muraoka D, Yamazaki N, Kuchiba A, Tanaka S, Michimae H, Ymada T, Hanada K, Okada,H, Takebe N, Hirano N, Okumura S, Sato D, Shibatsuji M, and Yamaguchi T.
Cancer Sci. 2015 Dec;106(12):1761-71. doi: 10.1111/cas.12819.

• Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine. 【PDF】

Tozuka M, Oka T, Jounai N, Egawa G, Ishii KJ, Kabashima K, and Takeshita F.
J Dermatol Sci. 2016 Apr;82(1):38-45. doi: 10.1016/j.jdermsci.2015.11.008. Epub 2015 Nov 22.

• Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant.

Hayashi M, Aoshi T, Kogai Y, Nomi D, Haseda Y, Kuroda E, Kobiyama K, and Ishii KJ.
Vaccine. 2016 Jan 12;34(3):306-12. doi: 10.1016/j.vaccine.2015.11.059. Epub 2015 Dec 5.

• Profiles of microRNA networks in intestinal epithelial cells in a mouse model of colitis. 【PDF】

Lee J, Park EJ, Yuki Y, Ahmad S, Mizuguchi K, Ishii KJ, Shimaoka M, and Kiyono H.
Sci Rep. 2015 Dec 9;5:18174. doi: 10.1038/srep18174.

• Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.

Mochizuki S, Morishita H, Kobiyama K, Aoshi T, Ishii KJ, and Sakurai K.
J Control Release. 2015 Dec 28;220(Pt A):495-502. doi: 10.1016/j.jconrel.2015.11.008. Epub 2015 Nov 10.

• CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody. 【PDF】

Hiramatsu K, Serada S, Kobiyama K, Nakagawa S, Morimoto A, Matsuzaki S, Ueda Y, Fujimoto M, Yoshino K, Ishii KJ, Enomoto T, Kimura T, and Naka T.
Cancer Sci. 2015 Oct;106(10):1474-8. doi: 10.1111/cas.12738.

• TANK-binding kinase 1-dependent or -independent signaling elicits the cell-type-specific innate immune responses induced by the adenovirus vector.

Tsuzuki S, Tachibana M, Hemmi M, Yamaguchi T, Shoji M, Sakurai F, Kobiyama K, Kawabata K, Ishii KJ, Akira S, and Mizuguchi H. Int Immunol. 2016 Mar;28(3):105-15. doi: 10.1093/intimm/dxv058. Epub 2015 Oct 20.

• Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy.

Kobiyama K and Ishii KJ.
Gan To Kagaku Ryoho. 2015 Sep;42(9):1040-5. Japanese.

• Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.

Aoshi T, Haseda Y, Kobiyama K, Narita H, Sato H, Nankai H, Mochizuki S, Sakurai K, Katakai Y, Yasutomi Y, Kuroda E, Coban C, and Ishii KJ.
J Immunol Res. 2015;2015:316364. doi: 10.1155/2015/316364. Epub 2015 Aug 25.

• Prothymosin-alpha preconditioning activates TLR4-TRIF signaling to induce protection of ischemic retina.

Halder SK, Matsunaga H, Ishii KJ, and Ueda H.
J Neurochem. 2015 Dec;135(6):1161-77. doi: 10.1111/jnc.13356. Epub 2015 Oct 16.

• Cutaneous exposure to agglomerates of silica nanoparticles and allergen results in IgE-biased immune response and increased sensitivity to anaphylaxis in mice.

Hirai T, Yoshioka Y, Takahashi H, Ichihashi K, Udaka A, Mori T, Nishijima N, Yoshida T, Nagano K, Kamada H, Tsunoda S, Takagi T, Ishii KJ, Nabeshi H, Yoshikawa T, Higashisaka K, and Tsutsumi Y.
Part Fibre Toxicol. 2015 Jun 26;12:16. doi: 10.1186/s12989-015-0095-3.

• Genome-Derived Cytosolic DNA Mediates Type I Interferon-Dependent Rejection of B Cell Lymphoma Cells. 【PDF】

Shen YJ, Le Bert N, Chitre AA, Koo CX, Nga XH, Ho SS, Khatoo M, Tan NY, Ishii KJ, and Gasser S.
Cell Rep. 2015 Apr 21;11(3):460-73. doi: 10.1016/j.celrep.2015.03.041. Epub 2015 Apr 9.

• Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen. 【PDF】

Onishi M, Ozasa K, Kobiyama K, Ohata K, Kitano M, Taniguchi K, Homma T, Kobayashi M, Sato A, Katakai Y, Yasutomi Y, Wijaya E, Igarashi Y, Nakatsu N, Ise W, Inoue T, Yamada H, Vandenbon A, Standley DM, Kurosaki T, Coban C, Aoshi T, Kuroda E, and Ishii KJ.
J Immunol. 2015 Mar 15;194(6):2673-82. doi: 10.4049/jimmunol.1402027. Epub 2015 Feb 13.

• RNA Polymerase III Regulates Cytosolic RNA:DNA Hybrids and Intracellular MicroRNA Expression. 【PDF】

Koo CX, Kobiyama K, Shen YJ, LeBert N, Ahmad S, Khatoo M, Aoshi T, Gasser S, and Ishii KJ.
J Biol Chem. 2015 Mar 20;290(12):7463-73. doi: 10.1074/jbc.M115.636365. Epub 2015 Jan 26.

• TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. 【PDF】

Temizoz B, Kuroda E, Ohata K, Jounai N, Ozasa K, Kobiyama K, Aoshi T, and Ishii KJ.
Eur J Immunol. 2015 Apr;45(4):1159-69. doi: 10.1002/eji.201445132. Epub 2015 Feb 5.

2014

• Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin.

Natsuaki Y, Egawa G, Nakamizo S, Ono S, Hanakawa S, Okada T, Kusuba N, Otsuka A, Kitoh A, Honda T, Nakajima S, Tsuchiya S, Sugimoto Y, Ishii KJ, Tsutsui H, Yagita H, Iwakura Y, Kubo M, Ng LG, Hashimoto T, Fuentes J, Guttman-Yassky E, Miyachi Y, and Kabashima K.
Nat Immunol. 2014 Nov;15(11):1064-9. doi: 10.1038/ni.2992. Epub 2014 Sep 21.

• Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.

Piao Z, Akeda Y, Takeuchi D, Ishii KJ, Ubukata K, Briles DE, Tomono K, and Oishi K.
Vaccine. 2014 Sep 29;32(43):5607-13. doi: 10.1016/j.vaccine.2014.07.108. Epub 2014 Aug 12.

• Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.

Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, and Kawaoka Y.
Vaccine. Sep 15;32(41):5295-300. doi: 10.1016/j.vaccine.2014.07.079. Epub 2014 Aug 6.

• System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test. 【PDF】

Mizukami T, Momose H, Kuramitsu M, Takizawa K, Araki K, Furuhata K, Ishii KJ, Hamaguchi I, and Yamaguchi K.
PLoS One. 2014 Jul 10;9(7):e101835. doi: 10.1371/journal.pone.0101835. eCollection 2014.

• The Early Activation of CD8(+) T Cells Is Dependent on Type I IFN Signaling following Intramuscular Vaccination of Adenovirus Vector.

Hemmi M, Tachibana M, Tsuzuki S, Shoji M, Sakurai F, Kawabata K, Kobiyama K, Ishii KJ, Akira S, and Mizuguchi H.
Biomed Res Int. 2014;2014:158128. doi: 10.1155/2014/158128. Epub 2014 May 27.

• Protective Epitopes of the Plasmodium falciparum SERA5 Malaria Vaccine Reside in Intrinsically Unstructured N-Terminal Repetitive Sequences. 【PLoS One HP】

Yagi M, Bang G, Tougan T, Palacpac NM, Arisue N, Aoshi T, Matsumoto Y, Ishii KJ, Egwang TG, Druilhe P, and Horii T.
PLoS One. 2014 Jun 2;9(6):e98460. doi: 10.1371/journal.pone.0098460. eCollection 2014.

• Olfactory plays a key role in spatiotemporal pathogenesis of cerebral malaria.

Zhao H, Aoshi T, Kawai S, Mori Y, Konishi A, Ozkan M, Fujita Y, Haseda Y, Shimizu M, Kohyama M, Kobiyama K, Eto K, Nabekura J, Horii T, Ishino T, Yuda M, Hemmi H, Kaisho T, Akira S, Kinoshita M, Tohyama K, Yoshioka Y, Ishii KJ, and Coban C.
Cell Host Microbe. 2014 May 14;15(5):551-63. doi: 10.1016/j.chom.2014.04.008.

• Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.

Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Sato A, Coban C, and Ishii KJ.
Vaccine. 2014 May 23;32(25):3004-9. doi: 10.1016/j.vaccine.2014.03.072. Epub 2014 Apr 8.

• Nucleic acid sensing by T cells initiates Th2 cell differentiation.

Imanishi T, Ishihara C, Badr Mel S, Hashimoto-Tane A, Kimura Y, Kawai T, Takeuchi O, Ishii KJ, Taniguchi S, Noda T, Hirano H, Brombacher F, Barber GN, Akira S, and Saito T.
Nat Commun. 2014 Apr 10;5:3566. doi: 10.1038/ncomms4566.

• Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome.

Takemura N, Kawasaki T, Kunisawa J, Sato S, Lamichhane A, Kobiyama K, Aoshi T, Ito J, Mizuguchi K, Karuppuchamy T, Matsunaga K, Miyatake S, Mori N, Tsujimura T, Satoh T, Kumagai Y, Kawai T, Standley DM, Ishii KJ, Kiyono H, Akira S, and Uematsu S.
Nat Commun. 2014 Mar 18;5:3492. doi: 10.1038/ncomms4492.

• RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma.

Lam AR, Le Bert N, Ho SS, Shen YJ, Tang ML, Xiong GM, Croxford JL, Koo CX, Ishii KJ, Akira S, Raulet DH, and Gasser S.
Cancer Res. 2014 Apr 15;74(8):2193-2203. doi: 10.1158/0008-5472.CAN-13-1703. Epub 2014 Mar 3.

• Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. 【PDF】 【press release】

Kobiyama K, Aoshi T, Narita H, Kuroda E, Hayashi M, Tetsutani K, Koyama S, Mochizuki S, Sakurai K, Katakai Y, Yasutomi Y, Saijo S, Iwakura Y, Akira S, Coban C, and Ishii KJ.
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3086-91. doi: 10.1073/pnas.1319268111. Epub 2014 Feb 10.

2013

• Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells. 【PDF】

Ono C, Ninomiya A, Yamamoto S, Abe T, Wen X, Fukuhara T, Sasai M, Yamamoto M, Saitoh T, Satoh T, Kawai T, Ishii KJ, Akira S, Okamoto T, and Matsuura Y.
J Virol. 2014 Feb;88(4):2157-67. doi: 10.1128/JVI.03055-13. Epub 2013 Dec 11.

• Development and application of next generation SE36 malaria vaccine formulated with a novel adjuvant: approach to travelers’ vaccine. 【PDF】

Tougan T, Ishii KJ, and Horii T.
Yakugaku Zasshi. 2013;133(11):1153-7. Japanese.

• DNA vaccines: A simple DNA sensing matter? 【PDF】

Coban C, Kobiyama K, Jounai N, Tozuka M, and Ishii KJ.
Hum Vaccin Immunother. 2013 Oct;9(10):2216-21. doi: 10.4161/hv.25893. Epub 2013 Aug 2.

• Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination 【PDF】

Kobiyama K, Jounai N, Aoshi T, Tozuka M, Takeshita F, Coban C, and Ishii KJ.
Vaccines. 2013 Jul 18;1(3):278-92. doi: 10.3390/vaccines1030278.

• Role of Extrachromosomal Histone H2B on Recognition of DNA Viruses and Cell Damage. 【PDF】

Kobiyama K, Kawashima A, Jounai N, Takeshita F, Ishii KJ, Ito T, and Suzuki K.
Front Genet. 2013 May 23;4:91. doi: 10.3389/fgene.2013.00091. eCollection 2013.

• Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36. 【PDF】

Palacpac NM, Ntege E, Yeka A, Balikagala B, Suzuki N, Shirai H, Yagi M, Ito K, Fukushima W, Hirota Y, Nsereko C, Okada T, Kanoi BN, Tetsutani K, Arisue N, Itagaki S, Tougan T, Ishii KJ, Ueda S, Egwang TG, and Horii T.
PLoS One. 2013 May 28;8(5):e64073. doi: 10.1371/journal.pone.0064073. Print 2013.

• Retinal cell type-specific prevention of ischemia-induced damages by LPS-TLR4 signaling through microglia.

Halder SK, Matsunaga H, Ishii KJ, Akira S, Miyake K, and Ueda H.
J Neurochem. 2013 Jul;126(2):243-60. doi: 10.1111/jnc.12262. Epub 2013 May 13.

• Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. 【PDF】

Kuroda E, Coban C, and Ishii KJ.
Int Rev Immunol. 2013 Apr;32(2):209-20. doi: 10.3109/08830185.2013.773326.

• The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant. 【PDF】

Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama K, Dessailly BH, Kuroda E, Akira S, Mizuguchi K, Coban C, and Ishii KJ.
PLoS One. 2013;8(3):e60038. doi: 10.1371/journal.pone.0060038. Epub 2013 Mar 21.

• DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking 【PDF】

Kondo T, Kobayashi J, Saitoh T, Maruyama K, Ishii KJ, Barber GN, Komatsu K, Akira S, and Kawai T.
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2969-74. doi: 10.1073/pnas.1222694110. Epub 2013 Feb 6.

• Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. 【PDF】

Jounai N, Kobiyama K, Takeshita F, and Ishii KJ.
Front Cell Infect Microbiol. 2013 Jan 8;2:168. doi: 10.3389/fcimb.2012.00168. eCollection 2012.

• TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.

Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, Ishii KJ, and Horii T.
Hum Vaccin Immunother. 2013 Feb;9(2):283-90. Epub 2013 Jan 4.

2012

• Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.

Shiraishi K, Hamano M, Ma H, Kawano K, Maitani Y, Aoshi T, Ishii KJ, and Yokoyama M.
J Control Release. 2013 Feb 10;165(3):183-90. doi: 10.1016/j.jconrel.2012.11.016. Epub 2012 Dec 3.

• Lipocalin 2 bolsters innate and adaptive immune responses to blood-stage malaria infection by reinforcing host iron metabolism.

Zhao H, Konishi A, Fujita Y, Yagi M, Ohata K, Aoshi T, Itagaki S, Sato S, Narita H, Abdelgelil NH, Inoue M, Culleton R, Kaneko O, Nakagawa A, Horii T, Akira S, Ishii KJ, and Coban C.
Cell Host Microbe. 2012 Nov 15;12(5):705-16. doi: 10.1016/j.chom.2012.10.010.

• Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children.

Nakayama T, Kumagai T, Ishii KJ, and Ihara T.
Vaccine. 2012 Dec 14;30(52):7662-6. doi: 10.1016/j.vaccine.2012.10.006. Epub 2012 Oct 24.

• Adjuvants in influenza vaccines.

Tetsutani K and Ishii KJ.
Vaccine. 2012 Dec 14;30(52):7658-61. doi: 10.1016/j.vaccine.2012.10.007. Epub 2012 Oct 19.

• Type-I IFN signaling is required for the induction of antigen-specific CD8(+) T cell responses by adenovirus vector vaccine in the gut-mucosa.

Shoji M, Tachibana M, Katayama K, Tomita K, Tsuzuki S, Sakurai F, Kawabata K, Ishii KJ, Akira S, and Mizuguchi H.
Biochem Biophys Res Commun. 2012 Aug 17;425(1):89-93. doi: 10.1016/j.bbrc.2012.07.056. Epub 2012 Jul 20 PMID:22819843

• Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Desmet CJ and Ishii KJ.
Nat Rev Immunol. 2012 Jun 22;12(7):479-91. doi: 10.1038/nri3247.

• Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions.

Nakayama T, Kashiwagi Y, Kawashima H, Kumagai T, Ishii KJ, and Ihara T.
Vaccine. 2012 Jun 6;30(26):3885-90. doi: 10.1016/j.vaccine.2012.04.004. Epub 2012 Apr 13.

• A critical role of IL-33 in experimental allergic rhinitis.

Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y, Fujieda S, Yasuda M, Hisa Y, Akira S, Nakanishi K, and Yoshimoto T.
J Allergy Clin Immunol. 2012 Jul;130(1):184-94.e11. doi: 10.1016/j.jaci.2012.02.013. Epub 2012 Mar 27.

• Contribution of IL-33-activated type II innate lymphoid cells to pulmonar eosinophilia in intestinal nematode-infected mice. 【PDF】

Yasuda K, Muto T, Kawagoe T, Matsumoto M, Sasaki Y, Matsushita K, Taki Y,Futatsugi-Yumikura S, Tsutsui H, Ishii KJ, Yoshimoto T, Akira S, and Nakanishi K.
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3451-6. doi: 10.1073/pnas.1201042109. Epub 2012 Feb 13.

• Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T.
Vaccine.2011 Aug 11;29(35):5837-45.

2011

• Innate and adaptive immune responses to viral infection and vaccination.

Aoshi T, Koyama S, Kobiyama K, Akira S, and Ishii KJ.
Curr Opin Virol. 2011 Oct;1(4):226-32. doi: 10.1016/j.coviro.2011.07.002. Epub 2011 Jul 30.

• Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. 【PDF】

ZYildiz Zeyrek F, Palacpac N, Yuksel F, Yagi M, Honjo K, Fujita Y, Arisue N, Takeo S, Tanabe K, Horii T, Tsuboi T, Ishii KJ , and Coban C.
PLoS One . 2011;6(11):e28126. doi: 10.1371/journal.pone.0028126. Epub 2011 Nov 29.

• Novel Strategies to Improve DNA Vaccine Immunogenicity.

Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, and Ishii KJ.
Curr Gene Ther. 2011 Dec;11(6):479-84.

• Mycobacterial hypersensitivity pneumonitis requires TLR9-MyD88 in lung CD11b+CD11c+ cells. 【PDF】

Daito H, Kikuchi T, Sakakibara T, Gomi K, Damayanti T, Zaini J, Tode N,Kanehira M, Koyama S, Fujimura S, Ebina M, Ishii KJ, Akira S, Takai T, WatanabeA, and Nukiwa T.
Eur Respir J. 2011 Sep;38(3):688-701. doi: 10.1183/09031936.00177110. Epub 2011 Jan 27.

• DNA released from dying host cells mediates aluminum adjuvant activity.

Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, Bureau F, and Desmet CJ.
Nat Med. 2011 Jul 17;17(8):996-1002. doi: 10.1038/nm.2403.

• Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

Palacpac NM, Arisue N, Tougan T, Ishii KJ, and Horii T.
Vaccine. 2011 Aug 11;29(35):5837-45. doi: 10.1016/j.vaccine.2011.06.052. Epub 2011 Jun 28.

• A New Subset of CD103+CD8{alpha}+ Dendritic Cells in the Small Intestine Expresses TLR3, TLR7, and TLR9 and Induces Th1 Response and CTL Activity. 【PDF】

Fujimoto K, Karuppuchamy T, Takemura N, Shimohigoshi M, Machida T, Haseda Y, Aoshi T, Ishii KJ, Akira S, and Uematsu S.
J Immunol. 2011 Jun 1;186(11):6287-95. doi: 10.4049/jimmunol.1004036. Epub 2011 Apr 27.

• Silica Crystals and Aluminum Salts Regulate the Production of Prostaglandin in Macrophages via NALP3 Inflammasome-Independent Mechanisms.

Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, Aritake K, Urade Y, and Morimoto Y.
Immunity. 2011 Jun 1;186(11):6287-95. doi: 10.4049/jimmunol.1004036. Epub 2011 Apr 27.

• Fragments of Genomic DNA Released by Injured Cells Activate Innate Immunity andSuppress Endocrine Function in the Thyroid. 【PDF】

Kawashima A, Tanigawa K, Akama T, Wu H, Sue M, Yoshihara A, Ishido Y, Kobiyama K, Takeshita F, Ishii KJ, Hirano H, Kimura H, Sakai T, Ishii N, and Suzuki K.
Endocrinology. 2011 Apr;152(4):1702-12. doi: 10.1210/en.2010-1132. Epub 2011 Feb 8.

• Intranasal vaccination with pneumococcal surface protein A plus poly(I:C)protects against secondary pneumococcal pneumonia in mice.

Ezoe H, Akeda Y, Piao Z, Aoshi T, Koyama S, Tanimoto T, Ishii KJ, and Oishi K.
Vaccine. 2011 Feb 17;29(9):1754-61. doi: 10.1016/j.vaccine.2010.12.117. Epub 2011 Jan 8.

• NLRP4 Negatively Regulates Autophagic Processes through an Association with Beclin1.

Jounai N, Kobiyama K, Shiina M, Ogata K, Ishii KJ, amd Takeshita F.
J Immunol. 2011 Feb 1;186(3):1646-55. doi: 10.4049/jimmunol.1001654. Epub 2011 Jan 5.

2010 & before

• Modulation of intracellular signaling using protein-transduction technology

Kobiyama K, Jounai N, Ishii KJ, Horii T, Suzuki K, Ryo A, and Takeshita F.
Crit Rev Immunol. 2010;30(5):395-421.

• Induction of type I interferon by adenovirus-encoded small RNAs. 【PDF】

Yamaguchi T, Kawabata K, Kouyama E, Ishii KJ, Katayama K, Suzuki T, Kurachi S, Sakurai F, Akira S, and Mizuguchi H.
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17286-91. doi: 10.1073/pnas.1009823107. Epub 2010 Sep 20.

• TLR9 and endogenous adjuvants of thewhole blood-stage malaria vaccine.

Coban C, Horii T, Akira S, and Ishii KJ.
Expert Rev Vaccines. 2010 Jul;9(7):775-84. doi: 10.1586/erv.10.60.

• Evidences of protection against blood-stage infection of Plasmodium falciparum bythe novel protein vaccine SE36.

Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N,Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, and Takahashi M.
Parasitol Int. 2010 Sep;59(3):380-6. doi: 10.1016/j.parint.2010.05.002. Epub 2010 May 20.

• The Malarial Metabolite Hemozoin and Its Potential Use as a Vaccine Adjuvant.

Coban C, Yagi M, Ohata K, Igari Y, Tsukui T, Horii T, Ishii KJ, and Akira S.
Allergol Int. 2010 Jun;59(2):115-24. doi: 10.2332/allergolint.10-RAI-0194. Epub 2010 Apr 24.

• Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. 【PDF】

Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, Sakurai K, Coban C, Horii T, Akira S, and Ishii KJ.
Sci Transl Med. 2010 Mar 31;2(25):25ra24. doi: 10.1126/scitranslmed.3000759.

• Immunogenicity of whole parasite vaccines against Plasmodium Falciparum involves malarial hemozoin and host TLR9.

Coban C, Igari Y, Yagi M, Reimer T, Koyama S, Aoshi T, Ohata K, Tsukui T, Takeshita F, Sakurai K, Ikegami T, Nakagawa A, Horii T, Nunez G, Ishii KJ, and Akira S.
Cell Host Microbe. 2010 Jan 21;7(1):50-61. doi: 10.1016/j.chom.2009.12.003.

• Immune interventions of human diseases through toll-like receptors.

Coban C, Ishii KJ, and Akira S.
Adv Exp Med Biol. 2009;655:63-80. doi: 10.1007/978-1-4419-1132-2_7.

• Experimental Cerebral Malaria Progresses Independently of the Nlrp3 Inflammasome.

Reimer T, Shaw MH, Franchi L, Coban C, Ishii KJ, Akira S, Horii T, Rodriguez A, and Nunez G.
Eur J Immunol. 2010 Mar;40(3):764-9. doi: 10.1002/eji.200939996.

• Extra-chromosomal histone H2B mediates innate antiviral immune responses induced by intracellular double-stranded DNA. 【PDF】

Kobiyama K, Takeshita F, Jounai N, Sakaue-Sawano A, Miyawaki A, Ishii KJ, Kawai T, Sasaki S, Hirano H, Ishii N, Okuda K, and Suzuki K.
J Virol. 2010 Jan;84(2):822-32. doi: 10.1128/JVI.01339-09. Epub 2009 Nov 11.

• Bacterial DNA induces interleukin-12 production through Toll-like receptor 9-dependent pathways in the mouse lung.

Yamada H, Ishii KJ, and Yamaguchi O
J Jon Soc Intensive Care Med. 2009; 16 447-452

• Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response.

Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, Matsunaga K, Kageyama S, Omori H, Noda T, Yamamoto N, Kawai T, Ishii K, Takeuchi O, Yoshimori T, and Akira S.
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20842-6. doi: 10.1073/pnas.0911267106. Epub 2009 Nov 19.

• A host type-I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. 【PDF】

McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, Ishii KJ, Akira S, Colonna M, Chen ZJ, Fitzgerald KA, Hayakawa Y, and Vance RE.
J Exp Med. 2009 Aug 31;206(9):1899-911. doi: 10.1084/jem.20082874. Epub 2009 Aug 3.

• Innate immune control of nucleic acid-based vaccine immunogenicity.

Koyama S, Coban C, Aoshi T, Horii T, Akira S, and Ishii KJ.
Expert Rev Vaccines. 2009 Aug;8(8):1099-107. doi: 10.1586/erv.09.57.

• Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. 【PDF】

Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S, Takeuchi O, Ishii KJ, Kawai T, Akira S, and Matsuura Y.
J Virol. 2009 Aug;83(15):7629-40. doi: 10.1128/JVI.00679-09. Epub 2009 May 27.

• Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.

Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, Ishii KJ, Kataoka K, and Oishi K.
Vaccine. 2009 May 21;27(24):3181-8. doi: 10.1016/j.vaccine.2009.03.055. Epub 2009 Apr 8.

• A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. 【PDF】

Kobiyama K, Takeshita F, Ishii KJ, Koyama S, Aoshi T, Akira S, Sakaue-Sawano A, Miyawaki A, Yamanaka Y, Hirano H, Suzuki K, and Okuda K.
J Immunol. 2009 Feb 1;182(3):1593-601.

• Potential link between the immune system and metabolism of nucleic acids.

Ishii KJ* and Akira S*. (*Corresponding author)
Curr Opin Immunol. 2008 Oct;20(5):524-9. doi: 10.1016/j.coi.2008.07.002. Epub 2008 Aug 6.

• Innate immune response to viral infection.

Koyama S, Ishii KJ, Coban C, and Akira S.
Cytokine. 2008 Sep;43(3):336-41. doi: 10.1016/j.cyto.2008.07.009. Epub 2008 Aug 9.

• Intracellular DNA sensors in immunity.

Takeshita F and Ishii KJ*. (*Corresponding author)
Curr Opin Immunol. 2008 Aug;20(4):383-8. doi: 10.1016/j.coi.2008.05.009. Epub 2008 Jun 23.

• Host innate immune receptors and beyond: making sense of microbial infections.

Ishii KJ*, Koyama S, Nakagawa A, Coban C, and Akira S. (*Co-corresponding author)
Cell Host Microbe. 2008 Jun 12;3(6):352-63. doi: 10.1016/j.chom.2008.05.003.

• Molecular and cellular mechanisms of DNA vaccines. 【PDF】

Coban C, Koyama S, Takeshita F, Akira S, and Ishii KJ*. (*Corresponding author)
Hum Vaccin. 2008 Nov-Dec;4(6):453-6. Epub 2008 Nov 28.

• Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5.

Uematsu S, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M, Sato S, Tsujimura T, Yamamoto M, Yokota Y, Kiyono H, Miyasaka M, Ishii KJ, and Akira S.
Nat Immunol. 2008 Jul;9(7):769-76. doi: 10.1038/ni.1622. Epub 2008 May 30.

• TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.

Ishii KJ*, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, and Akira S*. (* Co-corresponding author)
Nature. 2008 Feb 7;451(7179):725-9. doi: 10.1038/nature06537.

• Malaria Parasites Require TLR9 Signaling for Immune Evasion by Activating Regulatory T Cells. 【PDF】

Hisaeda H, Tetsutani K, Imai T, Moriya C, Tu L, Hamano S, Duan X, Chou B, Ishida H, Aramaki A, Shen J, Ishii KJ, Coban C, Akira S, Takeda K, Yasutomo K, Torii M, and Himeno K.
J Immunol. 2008 Feb 15;180(4):2496-503.

• Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. 【PDF】

Kumar H, Koyama S, Ishii KJ, Kawai T, and Akira S.
J Immunol. 2008 Jan 15;180(2):683-7.

• Differential Role of TLR- and RLR-Signaling in the Immune Responses to Influenza A Virus Infection and Vaccination. 【PDF】

Koyama S, Ishii KJ*, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, and Akira S*. (* Co-corresponding author)
J Immunol. 2007 Oct 1;179(7):4711-20.

• Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency. 【PDF】

Yamamoto M, Uematsu S, Okamoto T, Matsuura Y, Sato S, Kumar H, Satoh T, Saitoh T, Takeda K, Ishii KJ, Takeuchi O, Kawai T, and Akira S.
J Exp Med. 2007 Sep 3;204(9):2233-9. Epub 2007 Aug 27.

• The Atg5 Atg12 conjugate associates with innate antiviral immune responses. 【PDF】

Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, Xin KQ, Ishii KJ, Kawai T, Akira S, Suzuki K, and Okuda K.
Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14050-5. Epub 2007 Aug 20.

• Blocking of the TLR5 Activation Domain Hampers Protective Potential of Flagellin DNA Vaccine. 【PDF】

Saha S, Takeshita F, Matsuda T, Jounai N, Kobiyama K, Matsumoto T, Sasaki S, Yoshida A, Xin KQ, Klinman DM, Uematsu S,Ishii KJ, Akira S, and Okuda K.
J Immunol. 2007 Jul 15;179(2):1147-54.

• A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells.

Shimada N, Coban C, Takeda Y, Mizu M, Minari J, Anada T, Torii Y, Shinkai S, Akira S, Ishii KJ, and Sakurai K.
Bioconjug Chem. 2007 Jul-Aug;18(4):1280-6. Epub 2007 May 27.

• Manipulation of host innate immune responses by the malaria parasite.

Coban C, Ishii KJ, Horii T, and Akira S.
Trends Microbiol. 2007 Jun;15(6):271-8. Epub 2007 Apr 26.

• Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development.

Ishii KJ and Akira S. (*Corresponding author)
J Clin Immunol. Jul;27(4):363-71. Epub 2007 Mar 17.

• Pathological role of Toll-like receptor signaling in cerebral malaria. 【PDF】

Coban C*, Ishii KJ*, Uematsu S, Arisue N, Sato S, Yamamoto M, Kawai T, Takeuchi O, Hisaeda H, Horii T, and Akira S. (* Co-first author)
Int Immunol. 2007 Jan;19(1):67-79. Epub 2006 Nov 29.

• Cutting Edge: Pivotal Function of Ubc13 in Thymocyte TCR Signaling. 【PDF】

Yamamoto M, Sato S, Saitoh T, Sakurai H, Uematsu S, Kawai T, Ishii KJ, Takeuchi O, and Akira S.
J Immunol. 2006 Dec 1;177(11):7520-4.

• ‘Toll’ gates for future immunotherapy.

Ishii KJ, Uematsu S, and Akira S.
Curr Pharm Des. 2006;12(32):4135-42.

• Synthesis and in Vitro Characterization of Antigen-Conjugated Polysaccharide as a CpG DNA Carrier.

Shimada N, Ishii KJ, Takeda Y, Coban C, Torii Y, Shinkai S, Akira S, and Sakurai K.
Bioconjug Chem. 2006 Sep-Oct;17(5):1136-40.

• Innate immune recognition of, and regulation by, DNA.

Ishii KJ and Akira S.
Trends Immunol. 2006 Nov;27(11):525-32. Epub 2006 Sep 18.

• Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling.

Yamamoto M, Okamoto T, Takeda K, Sato S, Sanjo H, Uematsu S, Saitoh T, Yamamoto N, Sakurai H, Ishii KJ, Yamaoka S, Kawai T, Matsuura Y, Takeuchi O, and Akira S.
Nat Immunol. 2006 Sep;7(9):962-70. Epub 2006 Jul 23.

• Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells.

Uematsu S, Jang MH, Chevrier N, Guo Z, Kumagai Y, Yamamoto M, Kato H, Sougawa N, Matsui H, Kuwata H, Hemmi H, Coban C, Kawai T, Ishii KJ, Takeuchi O, Miyasaka M, Takeda K, and Akira S.
Nat Immunol. 2006 Aug;7(8):868-74. Epub 2006 Jul 9.

• Contribution of interferon-beta to the immune activation induced by double-stranded DNA. 【PDF】

Shirota H, Ishii KJ, Takakuwa H, Klinman DM.
Immunology. 2006 Jul;118(3):302-10.

• Essential role of IPS-1 in innate immune responses against RNA viruses. 【PDF】

Kumar H, Kawai T, Kato H, Sato S, Takahashi K, Coban C, Yamamoto M, Uematsu S, Ishii KJ, Takeuchi O, and Akira S.
J Exp Med. 2006 Jul 10;203(7):1795-803. Epub 2006 Jun 19.

• Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. 【PDF】

Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N, Suzuki K, Klinman DM, Okuda K, and Sasaki S.
J Virol. 2006 Jul;80(13):6218-24.

• Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.

Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, and Akira S.
Nature. 2006 May 4;441(7089):101-5. Epub 2006 Apr 9.

• Manifold Mechanisms of Toll-Like Receptor-Ligand recognition.

Ishii KJ, Coban C, and Akira S.
J Clin Immunol. 2005 Nov;25(6):511-21.

• A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA.

Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, Takeshita F, Ludwig H, Sutter G, Suzuki K, Hemmi H, Sato S, Yamamoto M, Uematsu S, Kawai T, Takeuchi O, and Akira S.
Nat Immunol. 2006 Jan;7(1):40-8. Epub 2005 Nov 13.

• Th1-Like Cytokine Induction by Heat-Killed Brucella abortus Is Dependent on Triggering of TLR9. 【PDF】

Huang LY, Ishii KJ, Akira S, Aliberti J, and Golding B.
J Immunol. 2005 Sep 15;175(6):3964-70.

• IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, and Akira S.
Nat Immunol. 2005 Oct;6(10):981-8. Epub 2005 Aug 28.

• TLR ignores methylated RNA.

Ishii KJ and Akira S.
Immunity. 2005 Aug;23(2):111-3.

• Innate immune recognition of nucleic acids: Beyond toll-like receptors.

Ishii KJ and Akira S.
Int J Cancer. 2005 Nov 20;117(4):517-23.

• TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF.

Takeshita F, Ishii KJ, Kobiyama K, Kojima Y, Coban C, Sasaki S, Ishii N, Klinman DM, Okuda K, Akira S, and Suzuki K.
Eur J Immunol. 2005 Aug;35(8):2477-85.

• CpG-activated Thy1.2(+) dendritic cells protect against lethal Listeria monocytogenes infection.

Ishii KJ, Ito S, Tamura T, Hemmi H, Conover J, Ozato K, Akira S, and Klinman DM.
Eur J Immunol. 2005 Aug;35(8):2397-405.

• Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. 【PDF】

Coban C*, Ishii KJ*, Gursel M, Klinman DM,and Kumar N. (*Co-first author)
J Leukoc Biol. 2005 Sep;78(3):647-55. Epub 2005 Jun 16.

• Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes. 【PDF】

Ito S, Ishii KJ, Ihata A, and Klinman DM.
Infect Immun. 2005 Jun;73(6):3803-5.

• Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. 【PDF】

Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, and Akira S.
J Exp Med. 2005 Mar 21;201(6):915-23. Epub 2005 Mar 14.

• CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. 【PDF】

Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, Akira S, Klinman DM, and Ishii KJ*. (* Corresponding author)
J Immunol. 2005 Feb 15;174(4):2273-9.

• Supive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. 【PDF】

Dong L, Ito S, Ishii KJ, and Klinman DM.
Arthritis Rheum. 2005 Feb;52(2):651-8.

• CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. 【PDF】

Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, and Klinman DM.
J Immunol. 2005 Jan 15;174(2):777-82.

• Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. 【PDF】

Coban C*, Ishii KJ*, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O, Itagaki S, Kumar N, Horii T, and Akira S. (*Co-first author)
J Exp Med. 2005 Jan 3;201(1):19-25.

• Suppressive oligodeoxynecleotides inhibits CpG-induced inflammatory responses in the mouse lung.

Yamada H, Ishii KJ, and Klinman DM.
Crit Care Med. 2004 Oct;32(10):2045-9.

• Toll-like Receptors and Sepsis.

Ishii KJ and Akira S.
Curr .Dis Rep 2004 Oct;6(5):361-366.

• Therapeutic targeting of Toll-like receptors

Uematsu S, Ishii KJ, and Akira S.
Drug Discovery Today: Therapeutic Strategies. 2004 1(3): 299-304

• Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6.

Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M,Inoue J, Uematsu S, Takeuchi O, and Akira S.
Nat Immunol. 2004 Oct;5(10):1061-8. Epub 2004 Sep 7.

• Transcriptional regulation of human Toll like receptor 9 gene. 【PDF】

Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM, and Ishii KJ.
J Immunol. 2004 Aug 15;173(4):2552-61.

• Immunotherapeutic Utility of Stimulatory and Suppressive Oligonucleotides.

Ishii KJ, Gursel I, Gursel M, and Klinman DM.
Curr Opin Mol Ther. 2004 Apr;6(2):166-74.

• CpG Oligodeoxynucleotides Improve the Survival of Pregnant and Fetal Mice Following Listeria Monocytogenes Infection.

Ito S, Ishii KJ, Shirota H, Klinman DM.
Infect Immun. Jun;72(6):3543-8.

• Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. 【PDF】

Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, and Ozato K.
J Immunol. 2004 Jun 1;172(11):6820-7.

• Suppressive oligonucleotides protect against collagen-induced arthritis in mice. 【PDF】

Dong L, Ito S, Ishii KJ, and Klinman DM.
Arthritis Rheum. 2004 May;50(5):1686-9.

• Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.

Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, and Klinman DM.
Semin Immunol. 2004 Feb;16(1):17-22.

• Anti-tumor therapy with bacterial DNA and toxin: Liposomal CpG ODN plus IL-13 cytotoxin induces complete regression of established human tumor in animal models. 【PDF】
Ishii KJ*, Kawakami K, Gursel I, Klinman DM, and Puri RK. (* Corresponding author)


Clin Cancer Res. 2003 Dec 15;9(17):6516-22.

• Effect of CpG Oligodeoxynucleotides on the Immunogenicity og Pfs25, a Plasmodium falciparum Transmission Blocking Vaccine. 【PDF】

Coban C, Ishii KJ, Stowers AW, Keister DB, Klinman DM, and Kumar N.
Infect Immun. 2004 Jan;72(1):584-8.

• Repetitive Elements Present in Mammalian Telomeres Suppress Bacterial DNA Induced Immune Activation. 【PDF】

Gursel I, Yamada H, Gursel M, Ishii KJ, Takeshita F, and Klinman DM.
J Immunol. 2003 Aug 1;171(3):1393-400.

• Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. 【PDF】

Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, and Klinman DM.
Arthritis Rheum. 2003 Jun;48(6):1701-7.

• Response of PBMC from Lupus Patients to Stimulation by CpG Oligodeoxynucleotides.

Zeuner RA, Klinman DM, Illei G, Ishii KJ, Gursel M, and Verthelyi D.
Rheumatology. 2003 Apr;42(4):563-9.

• Effect of suppressive DNA on CpG-induced immune activation. 【PDF】

Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, and Klinman DM.
J Immunol. 2002 Nov 15;169(10):5590-4.

• Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides.

Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, and Verthelyi D.
Arthritis Rheum. 2002 Aug;46(8):2219-24.

• Potential Role of PI3 Kinases, rather than DNA-PK, in CpG DNA Induced Immune Activation 【PDF】

Ishii KJ, Takeshita F, Gursel I, Gursel M, Nussenzweig A, and Klinman DM.
J Exp Med. 2002 Jul 15;196(2):269-74.

• CpG DNA: recognition by and activation of monocytes.

Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, and Gursel M.
Microbes Infect. 2002 Jul;4(9):897-901.

• Purified malaria pigment hemozoin enhances dendritic cell maturation and modulates isotype of antibodies induced by DNA vaccine. 【PDF】

Coban C, Ishii KJ, Sullivan DJ, and Kumar N.
Infect Immun. 2002 Jul;70(7):3939-43.

• Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. 【PDF】

Gursel M, Verthelyi D, Gursel I, Ishii KJ, and Klinman DM.
J Leukoc Biol. 2002 May;71(5):813-20.

• Transfection of single-stranded hepatitis A virus RNA activates MHC class I pathway.

Suzuki K, Yanagi M, Mori-Aoki A, Moriyama E, Ishii KJ, and Kohn LD.
Clin Exp Immunol. 2002 Feb;127(2):234-42.

• Cutting Edge: Role of Toll-Like Receptor 9 in CpG DNA-Induced Activation of Human Cells.

Takeshita F, Leifer C, Gursel I, Gursel M, Ishii KJ, and Klinman DM.
J Immunol. 2001 Oct 1;167(7):3555-8.

• Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides.

Gursel I, Gursel M, Ishii KJ, and Klinman DM.
J Immunol. 2001 Sep 15;167(6):3324-8.

• Genomic DNA released by dying cells induces the maturation of antigen presenting cells.

Ishii KJ, Suzuki K, Itoh Y, Coban C, Takeshita F, Matoba H, Kohn LD, and Klinman DM.
J Immunol. 2001 Sep 1;167(5):2602-7.

• Human peripheral blood differentially recognize and respond to two distinct CpG motifs.

Verthelyi D, Ishii KJ, Gursel M, Takeshita F, and Klinman DM.
J Immunol. 2001 Feb 15;166(4):2372-7.

• DNA vaccines: capacity to induce auto-immunity and tolerance.

Klinman DM, Takeshita F, Kamstrup S, Takeshita S, Ishii K, Ichino M, Yamada H.
Dev Biol. 2000;104:45-51.

• Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression.

Takeshita F, Ishii KJ, Ueda A, Ishigatsubo Y, and Klinman DM.
Eur J Immunol. 2000 Jan;30(1):108-16.

• CpG DNA augments the immunogenicity of plasmid DNA vaccines.

Klinman DM, Ishii KJ, and Verthelyi D.
Curr Top Microbiol Immunol. 2000;247:131-42.

• Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Klinman DM, Kamstrup S, Verthelyi D, Gursel I, Ishii KJ, Takeshita F, and Gursel M.
Springer Semin Immunopathol. 2000;22(1-2):173-83.

• Immunotherapeutic applications of CpG-containing oligodeoxynucleotides.

Klinman DM, Ishii KJ, Gursel M, Gursel I Drug News and Perspective. 2000 Jun;13(5):289-96.

• CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression.

Takeshita S, Takeshita F, Haddad DE, Ishii KJ, and Klinman DM.
Cell Immunol. 2000 Dec 15;206(2):101-6.

• Immune recognition of foreign DNA.

Klinman DM, Verthelyi D, Takeshita F, and Ishii KJ.
Immunity. 1999 Aug;11(2):123-9.

• Activity and Safety of DNA Plasmids Encoding IL-4 and IFN gamma.

Ishii KJ, Weiss WR, Ichino M, Verthelyi D, Hoffman SL, and Klinman DM.
Gene Ther. 1999 Feb;6(2):237-44.

• Activation of target tissue immune recognition molecules by double strand polynucleotides.

Suzuki K, Mori A, Ishii KJ, Saito J, Singer DS, Klinman DM, Krause PR, and Kohn LD.
Proc Natl Acad Sci. 1999 Mar 2;96(5):2285-90.

• Factors associated with the development of neonatal tolerance after the administration of plasmid DNA vaccine.

Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, and Klinman DM.
J Immunol. 1999 Apr 1;162(7):3814-8.

• Prevention of neonatal tolerance by plasmid DNA encoding GMCSF.

Ishii KJ, Weiss WR, and Klinman DM.
Vaccine. 1999 Nov 12;18(7-8):703-10.

• A plasmid encoding murine granulocyte macrophage colony stimulating factor increases protection conferred by a malaria DNA vaccine.

Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, Klinman DM, and Hoffman SL.
J Immunol. 1998 Sep 1;161(5):2325-32.

• Intraoperative management for removal of tumor thrombus in the inferior Vena Cava or the right atrium with multiplane transesophageal echocardiography.

Koide Y, Mizoguchi T, Ishii K, and Okumura F.
J Cardiovasc Surg. 1998 Oct;39(5):641-7.

• Two cases of Rhabdomyolysis in a family.(Japanese)

Ishii K, Matsuura Y, Soga T, and Okumura F.
Anesthesia and Resuscitation. 1996 Vol32, Sup: 34

• Polymyositis and BOOP (bronchiolitis obliterans organizing pneumonia) with high macro creatinin kinase. Implication for risks of gastrointestinal cancer.

Ishii K, Suzuki J, and Okubo T.
Chirougaku (Japanese). 1994 28(2) 95-98.